Hooman has 30 years of business leadership experience. He has worked at two of the largest companies in the world — Medtronic and GE — and was a Corporate Officer of both. A global executive, he has lived in the UK and France. During his career he has built a for driving growth, particularly in challenging areas, by executing disruptive and transformational new technologies and through business model innovation.
Hooman is currently advising CEOs & Boards, with an emphasis in Medical Technology.
Relevant Experience
Hooman currently serves on the board of two private companies. Mpirik is a SaaS company which uses AI and big data to identify high-risk Cardiovascular patients who are in need of more specialized care or surgery. PathMaker Neurosystems is the only multi-site, non-invasive neuromodulation company that is focused on the treatment of spasticity and the suppression of ALS symptoms.
Previously, Hooman was an Executive Vice President and Group President for Medtronic, with P&L responsibility for the ~$2.5B Diabetes Group. The Group has 6,000 employees based in locations around the world. The business unit is a market leader in the field, is a DTC business & is accretive to the overall company growth rate. During his tenure, Hooman re-focused the Diabetes business, launched a transformational new product and drove market share to record levels. As a result, the Diabetes Group created $0.7B of incremental, organic growth for Medtronic, growing from $1.8B to approximately $2.5B in just six years. In addition, Hooman drove a more global presence by expanding manufacturing into new geographies and built the most comprehensive technology pipeline in the Group’s history, with a heavy emphasis on Data Science and AI.Prior to Medtronic, Hooman was the President of GE’s Detection & Guidance Solutions business. This $2B business comprised of 7 business units with 1,700 employees and 13 manufacturing facilities. During his tenure, Hooman drove market share, growth & expanded the company’s footprint internationally.
Personal
Hooman is married to Christine. They have been married for 25 years and have three children, Hannah, Cameron and Casey. He enjoys exercise, traveling and spending time with his family.
What is Hooman Hakami's net worth?
The estimated net worth of Hooman Hakami is at least $2.49 million as of September 10th, 2019. Mr. Hakami owns 30,761 shares of Medtronic stock worth more than $2,492,564 as of December 21st. This net worth approximation does not reflect any other assets that Mr. Hakami may own. Learn More about Hooman Hakami's net worth.
How do I contact Hooman Hakami?
Has Hooman Hakami been buying or selling shares of Medtronic?
Hooman Hakami has not been actively trading shares of Medtronic during the past quarter. Most recently, Hooman Hakami sold 82,877 shares of the business's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $107.31, for a transaction totalling $8,893,530.87. Following the completion of the sale, the executive vice president now directly owns 30,761 shares of the company's stock, valued at $3,300,962.91. Learn More on Hooman Hakami's trading history.
Who are Medtronic's active insiders?
Medtronic's insider roster includes Richard Anderson (Director), Michael Coyle (EVP), Gary Ellis (EVP), Hooman Hakami (EVP), Bryan Hanson (EVP), Omar Ishrak (Chairman), Richard Kuntz (SVP), Bradley Lerman (SVP), John Liddicoat (EVP), Michael Marinaro (EVP), Geoffrey Martha (Chairman of the Board & CEO), Karen Parkhill (CFO), Sean Salmon (EVP), Gregory Smith (EVP), Carol Surface (SVP), Rob Ten Hoedt (EVP), Brett Wall (EVP), Brett Wall (EVP), and Robert White (EVP). Learn More on Medtronic's active insiders.
Are insiders buying or selling shares of Medtronic?
During the last year, insiders at the medical technology company sold shares 3 times. They sold a total of 50,662 shares worth more than $4,285,162.92. The most recent insider tranaction occured on June, 7th when CEO Geoffrey Martha sold 19,113 shares worth more than $1,601,096.01. Insiders at Medtronic own 0.2% of the company.
Learn More about insider trades at Medtronic. Information on this page was last updated on 6/7/2024.
